StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide reported sales growth YoY (%) (%)

Form 8-K Product Sales Detail by Product and Geographic Region

Latest, FY2025
1.0%
Period ended Dec 31, 2025
Change on a year earlier
+50.0 pts
-49.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 20251.0%+50.0 ptsForm 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024-49.0%-24.0 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023-25.0%+10.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
FY2022Dec 31, 2022-35.0%-11.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021Dec 31, 2021-24.0%+5.0 ptsForm 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
FY2020Dec 31, 2020-29.0%-1.0 ptsForm 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
FY2019Dec 31, 2019-28.0%-27.0 ptsForm 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
FY2018Dec 31, 2018-1.0%–Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗

Cite this data

StockData. (2026). Amgen Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide reported sales growth YoY (%) (%), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_neulasta_yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.